Bioventus exercises option to acquire CartiHeal for $315M

Bioventus Inc. exercised its call option to acquire CartiHeal Ltd. for approximately $315 million, with an additional $135 million contingent on sales milestones, following FDA approval of CartiHeal's Agili-C implant.

“CartiHeal represents an important breakthrough for the treatment of osteoarthritis, and we are excited to bring this complementary product into our growing portfolio of medical devices.”bioventus.com

• 1 source
• bioventus.comBioventus Exercises Call Option to Acquire CartiHeal - BioventusApr 4, 2022

Summarized from public sources; check the original articles before acting on it.